TAK · Insider Trading
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Every open-market purchase and sale reported by TAK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | Lauren Rusckowski Duprey | Chief Transformation Officer | Sell | −34,535 | −$640.28K |
| 2026-09-03 | Andrew Stewart Plump | President, R&D | Sell | −116,191 | −$2.15M |
| 2026-08-21 | Andrew Stewart Plump | President, R&D | Sell | −19,651 | −$363.35K |
| 2026-08-19 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell | −12,980 | −$235.12K |
| 2026-08-12 | Gabriele Ricci | Chief Data & Tech. Officer | Sell | −25,088 | −$429.00K |
| 2026-08-12 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell | −6,774 | −$115.84K |
| 2026-08-12 | Julie So-Young Kim | President and CEO | Sell | −89,090 | −$1.52M |
| 2026-08-12 | Teresa Marie Bitetti | President, OBU | Sell | −50,012 | −$855.21K |
| 2026-08-12 | Giles Richard Platford | President, IBU | Sell | −31,083 | −$531.52K |
| 2026-08-12 | Andrew Stewart Plump | President, R&D | Sell | −165,393 | −$2.83M |
| 2026-08-12 | Lauren Rusckowski Duprey | Chief Transformation Officer | Sell | −47,586 | −$813.72K |
| 2026-08-12 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell | −34,603 | −$605.78K |
| 2026-08-12 | Elaine Mary Shannon | Pres., Global Supply & Quality | Sell | −20,363 | −$357.37K |
| 2026-08-12 | Ramy Riad Ahmed Ibrahim | President, PDT BU | Sell | −7,277 | −$124.44K |
| 2026-08-12 | Awny Samaan Botros Farajallah | Chief Medical Officer | Sell | −14,006 | −$239.50K |
| 2026-08-12 | Natalie Anne Marie Furney | Global General Counsel | Sell | −30,868 | −$527.84K |
| 2026-08-12 | Elaine Mary Shannon | Pres., Global Supply & Quality | Sell | −3,978 | −$68.02K |
| 2026-08-12 | Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev | Sell | −22,957 | −$392.56K |
| 2026-08-12 | Rhonda Janice Pacheco | President, U.S. Business Unit | Sell | −16,901 | −$289.01K |
| 2026-07-06 | Ramy Riad Ahmed Ibrahim | President, PDT BU | A | +25,078 | — |
| 2026-07-06 | Jennifer Marie Smoter | Chief Comm. & Gov. Officer | A | +18,808 | — |
| 2026-07-06 | Rhonda Janice Pacheco | President, U.S. Business Unit | A | +50,156 | — |
| 2026-07-06 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | A | +22,570 | — |
| 2026-07-06 | Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev. | A | +27,586 | — |
| 2026-07-06 | Teresa Marie Bitetti | President, OBU | A | +43,886 | — |
| 2026-07-06 | Elaine Mary Shannon | Pres., Global Supply & Quality | A | +30,094 | — |
| 2026-07-06 | Bruce D Broussard | Director | A | +3,800 | — |
| 2026-07-06 | Koichiro Kimura | Director | A | +1,800 | — |
| 2026-07-06 | Giles Richard Platford | President, IBU | A | +49,558 | — |
| 2026-07-06 | Miki Tsusaka | Director | A | +1,800 | — |
| 2026-07-06 | Lauren Rusckowski Duprey | Chief Transformation Officer | A | +45,140 | — |
| 2026-07-06 | Gabriele Ricci | Chief Data & Tech. Officer | A | +37,616 | — |
| 2026-07-06 | Paulus Stoffels | Director | A | +3,800 | — |
| 2026-07-06 | Awny Samaan Botros Farajallah | Chief Medical Officer | A | +17,554 | — |
| 2026-07-06 | Natalie Anne Marie Furney | Global General Counsel | A | +43,886 | — |
| 2026-07-06 | Milano Furuta | Chief Financial Officer | A | +12,300 | — |
| 2026-07-06 | Julie So-Young Kim | President and CEO | A | +73,234 | — |
| 2026-07-06 | Asuka Miyabashira | President, Japan Pharma B.U. | A | +1,500 | — |
| 2026-07-06 | Steven Gillis | Director | A | +3,800 | — |
| 2026-07-06 | Kimberly A. Reed | Director | A | +3,800 | — |
| 2026-07-06 | Masami Iijima | Director | A | +1,800 | — |
| 2026-07-06 | Andrew Stewart Plump | President, R&D | A | +125,390 | — |
| 2026-07-06 | John Maraganore | Director | A | +3,800 | — |
| 2026-04-28 | Julie So-Young Kim | CEO - Elect | A | +105,416 | — |
| 2026-04-28 | Teresa Marie Bitetti | President, OBU | A | +64,988 | — |
| 2026-04-28 | Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev. | A | +27,740 | — |
| 2026-04-28 | Lauren Rusckowski Duprey | Chief Transformation Officer | A | +59,990 | — |
| 2026-04-28 | Andrew Stewart Plump | President, R&D | A | +212,470 | — |
| 2026-04-28 | Milano Furuta | Chief Financial Officer | A | +7,800 | — |
| 2026-04-28 | Giles Richard Platford | President, IBU | A | +72,124 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Christophe Pierre Weber | President and CEO | 1,014,200 | $20.61M |
| Andrew Stewart Plump | President, R&D | 912,034 | $18.53M |
| Julie So-Young Kim | President and CEO | 391,489 | $7.96M |
| Giles Richard Platford | President, IBU | 315,838 | $6.42M |
| Teresa Marie Bitetti | President, OBU | 252,010 | $5.12M |
| Natalie Anne Marie Furney | Global General Counsel | 204,298 | $4.15M |
| Lauren Rusckowski Duprey | Chief Transformation Officer | 191,522 | $3.89M |
| Rhonda Janice Pacheco | President, U.S. Business Unit | 182,507 | $3.71M |
| Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev | 176,977 | $3.60M |
| Gabriele Ricci | Chief Data & Tech. Officer | 171,654 | $3.49M |
| Awny Samaan Botros Farajallah | Chief Medical Officer | 116,177 | $2.36M |
| Ramy Riad Ahmed Ibrahim | President, PDT BU | 102,588 | $2.08M |
| Milano Furuta | Chief Financial Officer | 70,200 | $1.43M |
| Elaine Mary Shannon | Pres., Global Supply & Quality | 63,333 | $1.29M |
| Nicola Deidre Petal Greenway | Chief Human Resources Officer | 40,049 | $813.80K |
| Jennifer Marie Smoter | Chief Comm. & Gov. Officer | 18,808 | $382.18K |
| Kimberly A. Reed | Director | 15,175 | $308.36K |
| Masami Iijima | Director | 14,601 | $296.69K |
| John Maraganore | Director | 13,800 | $280.42K |
| Steven Gillis | Director | 10,400 | $211.33K |
| Miki Tsusaka | Director | 8,200 | $166.62K |
| Bruce D Broussard | Director | 4,595 | $93.37K |
| Asuka Miyabashira | President, Japan Pharma B.U. | 4,500 | $91.44K |
| Paulus Stoffels | Director | 3,800 | $77.22K |
| Koichiro Kimura | Director | 1,800 | $36.58K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TAK quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.